Chief Executive Officer
Enrique Conterno joined FibroGen, Inc. as our Chief Executive Office and member of our board of directors in January 2020. Before coming to FibroGen, Mr. Conterno was a Senior Vice President for Eli Lilly and Company, serving as President of Lilly USA from January 2017 and President of Lilly Diabetes from 2009 until his retirement from Lilly in December 2019. Prior to 2009, Mr. Conterno served in various other roles for Eli Lilly and Company, including President, U.S. Operations, Vice President for the U.S. Neuroscience Business Unit, President and General Manager, Mexico, and Executive Marketing Director, Intercontinental Operations and Japan. Mr. Conterno earned a B.S. degree in Mechanical Engineering from Case Western Reserve University and an M.B.A. degree from Duke University. Mr. Conterno is a member of the Board of Governors at the American Red Cross, and the Board of Visitors at Duke University’s Fuqua School of Business.
Percy H. Carter, M.B.A., Ph.D.
Chief Scientific Officer
Dr. Carter, Chief Scientific Officer, joined FibroGen in September of 2020. Dr. Carter oversees FibroGen’s scientific and preclinical efforts. He brings more than 20 years of global biopharmaceutical leadership and experience, with deep expertise in drug discovery.
Prior to joining FibroGen, Percy served as Global Head of Discovery Sciences at Janssen, worked in collaboration with therapeutic area discovery scientists and other stakeholders to define and operationalize innovative strategies for the successful identification and optimization of novel small molecule, peptide, and RNA-based drug candidates. Prior to his role with Janssen, Percy was Senior Vice President and Head of Discovery for Bristol-Myers Squibb (BMS).
Prior to that, he was Senior Vice President and Head of Discovery Chemistry & Molecular Technologies and was Site Lead for the Biocon-BMS R&D Center in Bangalore, India. Percy began his career as a Senior Research Scientist in Chemical and Physical Sciences at DuPont Pharmaceuticals. Dr. Carter received his bachelor’s degree in Organic Chemistry from Dartmouth College, his Ph.D. in Chemistry & Chemical Biology from Harvard University, and completed a post-doctoral fellowship at Harvard Medical School and Massachusetts General Hospital. In 2014, he received his M.B.A. from the Massachusetts Institute of Technology.
Christine L. Chung
Senior Vice President, China Operations
Ms. Chung, Senior Vice President, China Operations, and Managing Director of our subsidiary company, FibroGen China. She joined the company in 2007 and brings more than 25 years of experience in growing businesses from start-up through various phases of corporate development. Ms. Chung serves in the role of Project Leader of our U.S.-based China development efforts and has overall responsibility for our China local operations. Under Ms. Chung’s leadership, our China strategy has advanced from conceptualization to pre-launch stage. Prior to joining FibroGen, Ms. Chung was Vice President, Business Development, at eMed Technologies and a management consultant with Monitor Group, the predecessor company of Monitor Deloitte. Ms. Chung received her B.A., magna cum laude, from Harvard University and is a native of Hong Kong.
Chief Financial Officer
Mr. Cotroneo is our Chief Financial Officer, with responsibility for finance and accounting operations, Human Resources, and Information Technology. Mr. Cotroneo joined FibroGen in 2000 and has served as our CFO since 2008. Mr. Cotroneo brings 25 years experience in senior financial management in the life sciences sector. Prior to joining FibroGen, Mr. Cotroneo was at SyStemix, Inc. where he assumed Controller responsibilities for both SyStemix and for Genetic Therapy, Inc. (now Novartis) from 1993 to 2000. Prior to Novartis, Mr. Cotroneo was employed for seven years by Deloitte. Mr. Cotroneo received a B.S. degree with honors from the University of San Francisco and was selected as a Louise M. Davies Scholar.
Mark Eisner, M.D., M.P.H.
Chief Medical Officer
Dr. Eisner, Chief Medical Officer, joined the Company in December of 2020. Dr. Eisner oversees all global clinical development and regulatory affairs for FibroGen. Dr. Eisner brings nearly 30 years of academic, biopharmaceutical, and drug development experience, from early clinical phase through post-commercialization. Prior to joining FibroGen, Dr. Eisner was at Genentech, a member of the Roche Group, and was Senior Vice President and Global Head of Product Development Immunology, Infectious Disease, and Ophthalmology. He also served on the Board of the Genentech Foundation, a private charitable foundation that supports educational and community organizations.
Prior to Genentech, Mark was Professor of Medicine and Anesthesia at the University of California San Francisco. Dr. Eisner received an A.B. degree from Stanford University in Human Biology and then received his M.D. degree from the University of Pennsylvania School of Medicine. He completed residency training in internal medicine, served as Chief Medical Resident, and pursued advanced fellowship training in pulmonary and critical care medicine at the University of California, San Francisco. He also received a M.P.H. degree from the University of California, Berkeley School of Public Health.
Vice President, Human Resources
Mr. Farley is Vice President, Human Resources, and joined FibroGen in 2015. Mr. Farley has more than 30 years of human resources experience at several leading companies. Prior to joining FibroGen, Mr. Farley served as Vice President, Human Resources, at XenoPort, Inc. Previously, Mr. Farley worked at Amgen, where he oversaw HR activities for numerous Research and Development groups in Thousand Oaks, Seattle, and Burnaby, Canada. Mr. Farley has also held human resource and administrative leadership roles at ViroPharma (now Shire Plc), Sphinx Pharmaceuticals (now Eli Lilly), Eli Lilly and Company, and Hewlett Packard. Mr. Farley holds a B.S. degree in Industrial and Labor Relations from Syracuse University and an M.B.A. from Duke University.
R. Wayne Frost, Pharm.D., J.D.
Senior Vice President, Regulatory Affairs
Dr. Frost, Senior Vice President, Regulatory Affairs joined FibroGen in 2010, bringing more than 20 years of pharmaceutical industry experience in regulatory affairs and drug development. Prior to joining FibroGen, he served as Vice President of Regulatory Affairs and Quality Assurance at Sangart Metabasis Therapeutics Inc. (now Ligand Pharmaceuticals, Inc.), and Prometheus Laboratories Inc. Previously, Dr. Frost served as: Global Regulatory Leader for ARANESP® at Amgen; Regulatory Therapeutic Area Head for Respiratory, Allergy, Inflammation, Immunology and Oncology at Pfizer Global Research and Development; and Head of Regulatory for Local Anesthetics and Critical Care Therapeutics at Astra Pharmaceuticals (now AstraZeneca). He also worked at Bayer Pharmaceuticals in antibiotic drug development and at Key Pharmaceuticals, Inc. in drug delivery. Dr. Frost is a guest lecturer on Food and Drug Law at Yale University School of Medicine, Department of Pharmacoepidemiology and Public Health. He completed a Pharm.D. at Creighton University School of Pharmacy and a post-doctoral fellowship in pharmacokinetics/infectious diseases at The State University of New York at Buffalo. He received a J.D. from the University of Connecticut School of Law.
Elias Kouchakji, M.D.
Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance
Dr. Kouchakji, Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance, joined FibroGen in 2014, bringing more than 25 years of experience in product development, drug safety, and clinical practice. Previously, he served as Executive Medical Director, Safety, at Amgen, Inc., supporting the development and commercialization of Aranesp®, among other programs. Prior, Dr. Kouchakji was the Global Head Pharmacovigilance and Risk Management at Elan Pharmaceuticals, Inc. (now Perrigo Company plc), Head of U.S. Safety at Hoffmann-La Roche (Roche), and Director, Drug Safety and Pharmacovigilance at Serono (now EMD Serono). Prior to his transition to industry, Dr. Kouchakji was a practicing physician with specialization in surgery, having earned his M.D. at Damascus University.
Michael D. Lowenstein, J.D.
Chief Legal Officer
Mr. Lowenstein, Chief Legal Officer, joined the company in 2003. Mr. Lowenstein has nearly 20 years of legal practice with a particular emphasis on corporate and securities law and life science transactions. Prior to joining FibroGen, Mr. Lowenstein practiced at Wilson Sonsini Goodrich & Rosati, where he focused on corporate law, securities, mergers and acquisitions (M&A), and strategic transactions. He earned a J.D. from Columbia University, where he was a Harlan Fiske Stone Scholar, and a B.A., magna cum laude, from Brown University. Mr. Lowenstein is a member of the State Bar of California.
Michael J. Martinelli, Ph.D.
Senior Vice President, Technical Development
Dr. Martinelli Senior Vice President, Technical Development, joined FibroGen in 2011. Dr. Martinelli has more than 30 years of experience in chemical research and development, automation technologies, and pharmaceutical research and development. He has headed the Chemistry, Manufacturing, and Controls (CMC) development of numerous investigational new drug (IND) programs, leading to many successful new drug applications (NDAs) and product launches. Most recently, he served as Vice President, Pharmaceutical Development for Arena Pharmaceuticals. Prior to joining Arena, he was Executive Director of Research, Chemical Process & Technologies, at Amgen Inc. Earlier in his career, Dr. Martinelli held numerous roles at Eli Lilly and Company, overseeing Chemical Process Research and Development. He completed post-doctoral fellowships at the University of Munich and Harvard University, and was elected as a Fellow to the Royal Society of Chemistry. Dr. Martinelli has organized many international scientific conferences, and is a reviewer for more than 10 scientific journals and an editor for scientific monographs. Dr. Martinelli received his B.S. in Chemistry from the State University of New York at Geneseo and a Ph.D. in Organic Chemistry from Wesleyan University.
Leanne C. Price, J.D.
Chief Intellectual Property Officer
Ms. Price, Chief Intellectual Property Officer, joined FibroGen in 1999. She has approximately 25 years of in-house and law firm experience with an emphasis on patent portfolio development and defense and intellectual property strategy in the biotechnology and pharmaceutical industries. Ms. Price was previously Senior Patent Attorney at Incyte Pharmaceuticals, where she was responsible for global management of Incyte’s core technology portfolio. Prior, Ms. Price was an associate at the Silicon Valley law firm of Skjerven Morrill MacPherson Franklin & Friel LLP, focused on the areas of patent prosecution and defense, licensing, and intellectual property counseling. Ms. Price received a B.S. in Molecular Biology and a B.A. in History Honors with high distinction from Revelle College at the University of California, San Diego. She received her J.D. from Boalt Hall, School of Law (University of California, Berkeley). Ms. Price is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office.
Chief Commercial Officer
Mr. Wettig, Chief Commercial Officer, joined FibroGen in June of 2020 and brings more than 30 years of global biopharmaceutical leadership and experience. Wettig, previously served as Chief Commercial Officer and Metabolic Franchise Head at Intarcia Therapeutics. Prior to joining Intarcia in 2018, Thane served as Vice President of Global Marketing, Strategy and Alliance Management for Lilly Diabetes, leading the development and launch of multiple blockbuster diabetes medicines during a period of unprecedented growth of Lilly’s diabetes business. Thane also played an integral role in the design and management of Lilly’s highly successful diabetes alliance between Lilly and Boehringer-Ingelheim. He is recognized throughout the industry as a seasoned executive with extensive launch experience. Mr. Wettig received his M.B.A. and B.A. in biology from Washington University in St. Louis.